
In 2003, the Office of Inspector General (OIG), Department of Health and Human Services, developed the OIG Compliance Program Guidance for Pharmaceutical Manufacturers. According to the OIG, “it is imperative for pharmaceutical manufacturers to establish and maintain effective compliance programs. These programs should foster a culture of compliance that begins at the executive level and permeates throughout the organization.” The OIG’s guidance includes seven widely recognized and fundamental elements to an effective compliance program. Amgen has gone a step further by identifying an additional three tenets to complete our Elements of an Effective Compliance Program. The OIG’s seven elements, combined with the additional three tenets identified by Amgen, are the foundation for our Worldwide Compliance & Business Ethics Program.
Core Elements of an Effective Compliance Program
Additional Tenets Identified by Amgen